BioWorld Asia

Dec. 10, 2003

Actelion, Merck Enter Oral Renin Inhibitor Pact Worth Up To $272M

Swiss biopharmaceutical firm Actelion Ltd. added $10 million to its cash pile, on the strength of an exclusive alliance with Merck & Co. Inc. in the area of oral renin inhibitors. (BioWorld International) Read More

Europe Fumbles Two Major Biotech-Related Decisions

'Reverse Vaccination' Might Help Stop Unwanted Immune Response

Clinical Trials Could Become More Difficult For Small Firms

PPL On The Block; Dolly's Creator Fades Into History

Cyclacel In-Licenses Cancer Compound From Sankyo Co.

Bavarian Nordic Investing In Production Facility, R&D

Stockholm Planning Bioscience Hub; Funding Concerns Remain

French Food Safety Agency Has Bt11 Sweet Corn Doubts

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Dec. 27, 2024.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for December 24, 2024.

Illustration of neurons with Lewy bodies

Enhanced Cognition: Lewy body dementia phase II pumps stock

BioWorld

Investors will get more details during the International Lewy Body Dementia Conference in Amsterdam late next month, but Wall Street is already buzzing about...

Experimental mRNA gene therapy suppresses preeclampsia in mice

BioWorld MedTech

A gene therapy based on an enhanced lipid nanoparticle (LNP) loaded with vascular endothelial growth factor (VEGF) mRNA could be developed for the treatment of...

Lab glassware and antibodies art concept

Probing bidirectional cancer-autoimmune link can yield new targets

BioWorld Science

Cancer and autoimmunity are “often thought of as being at opposite ends of the immune response,” Ana Anderson told her audience at a joint meeting of the NIH’s...